SYNAGEVA BIOPHARMA CORP
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | |
|---|---|---|---|---|---|---|
| Revenue | $1.6M | $5.1M | $15.0M | $2.1M | $595,000 | $161,830 |
| Operating income | −$36.5M | −$14.6M | −$43.0M | −$25.0M | −$13.1M | −$10.3M |
| Net income | −$36.4M | −$14.5M | −$42.9M | −$25.3M | −$10.8M | −$11.4M |
| Total assets | $504.2M | $447.9M | $243.3M | $83.3M | $17.0M | — |
| Total liabilities | $31.0M | $17.7M | $13.1M | $9.3M | $1.6M | — |
| Equity | $473.2M | $430.2M | $230.2M | $74.0M | −$80.2M | −$69.5M |
| EPS (diluted) | $-5.89 | $-3.40 | $-1.90 | $-8.58 | $-338.25 | — |
| Shares out. | 30.9M | 27.2M | 21.2M | 17.6M | 60,955 | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2014- Operating margin
- −2299.9%
- Net margin
- −2296.6%
- Return on equity
- −7.7%
- Return on assets
- −7.2%
- Return on capital (ROCE)
- −7.6%
- Liabilities / assets
- 6.1%
- Debt / equity
- 0.07×
- Book value / share
- $15.30
- Revenue growth (YoY)
- −69.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2014- Altman Z″ (distress)
- 18.30safe
- Accruals / assets
- 22.6%high accruals
- Piotroski F-Score
- 0/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 5 warning● 2 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 13, 2006
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Biggar Stephen R | Jun 22, 2015 | D | 102 | — |
| Baker Felix | Jun 22, 2015 | D | 200,526 | — |
| Quinn AnthonyOfficer — EVP, CMO, & Head of R&D | Jun 22, 2015 | Grant | 38 | $78.87 |
| Patel Sanj KOfficer — President & CEO | Jun 22, 2015 | D | 286 | — |
| Tisch Thomas JDirector | Jun 22, 2015 | D | 373,560 | — |
| Bazemore Robert BOfficer — Chief Operating Officer | Jun 22, 2015 | D | 35,000 | — |
| Boess CarstenOfficer — SVP, Chief Financial Officer | Jun 22, 2015 | D | 24,000 | — |
| Heberlig ChrisOfficer — SVP, Finance & Business Ops. | Jun 22, 2015 | Grant | 56 | $78.87 |
| Williams GlenOfficer — SVP, Technical Operations | Jun 22, 2015 | Grant | 56 | $78.87 |
| Malley ThomasDirector | Jun 22, 2015 | D | 46,901 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJun 23, 2015
- Entered a material agreement · Amended charter or bylaws · Other material eventMay 6, 2015
- Results of operationsApr 29, 2015
- Results of operationsFeb 26, 2015
- Entered a material agreementFeb 9, 2015
- Entered a material agreementFeb 2, 2015
- Other material eventJan 7, 2015
- Results of operationsOct 30, 2014
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 16, 2016
- 15-12GFORM 15Jul 6, 2015
- 3OWNERSHIP DOCUMENTJun 29, 2015
- SC 13D/AJun 24, 2015
- CT ORDERJun 24, 2015
- 4Jun 23, 2015
- 4Jun 23, 2015
- 4FORM 4 SUBMISSIONJun 23, 2015
- 4FORM 4 SUBMISSIONJun 23, 2015
- 4FORM 4 SUBMISSIONJun 23, 2015
- 4FORM 4 SUBMISSIONJun 23, 2015
- 4FORM 4 SUBMISSIONJun 23, 2015
- 4FORM 4 SUBMISSIONJun 23, 2015
- 4FORM 4 SUBMISSIONJun 23, 2015
- 4FORM 4 SUBMISSIONJun 23, 2015
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.